Current Report Filing (8-k)
May 09 2019 - 8:20AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(D)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): May 6, 2019
AKEBIA THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)
|
|
|
|
|
Delaware
|
|
001-36352
|
|
20-8756903
|
(State or other jurisdiction
of incorporation)
|
|
(Commission
File Number)
|
|
(IRS Employer
Identification No.)
|
|
|
|
245 First Street
Cambridge, Massachusetts
|
|
02142
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrants telephone number, including area code: (617)
871-2098
Check the appropriate box below
if the Form
8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐
|
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
☐
|
Soliciting material pursuant to Rule
14a-12
under the Exchange Act (17
CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule
14d-2(b)
under the Exchange Act (17 CFR
240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule
13e-4(c)
under the Exchange Act (17 CFR
240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this
chapter) or Rule
12b-2
of the Securities Exchange Act of 1934
(§ 240.12b-2
of this chapter).
Emerging growth company ☒
If an
emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☒
Securities registered pursuant to Section 12(b) of the Act:
|
|
|
|
|
Title of each class
|
|
Trading
symbol(s)
|
|
Name of each exchange
on which registered
|
Common Stock, par value $0.00001 per share
|
|
AKBA
|
|
The Nasdaq Global Market
|
Item 2.02 Results of Operations and Financial Condition.
On May 9, 2019, Akebia Therapeutics, Inc. (the Company) announced financial results for the quarter ended March 31, 2019 and commented on
certain corporate accomplishments and plans. The full text of the press release issued in connection with these announcements is furnished as Exhibit 99.1 to this Current Report on Form
8-K
(this
Report) and is incorporated by reference into this Item 2.02.
The information in this Item 2.02 and Exhibit 99.1 shall not be deemed
filed for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any
filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such a filing.
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain
Officers.
On May 6, 2019, Rita Jain, M.D., announced that she intends to resign her current position as the Companys Senior Vice President,
Chief Medical Officer, effective June 17, 2019. On May 9, 2019, the Company announced that Steven K. Burke, M.D., will succeed Dr. Jain as the Companys Senior Vice President, Chief Medical Officer on the effective date of
Dr. Jains resignation. Dr. Jain has advised the Company that she is committed to supporting the Company and her successor during a transitional period.
Item 9.01 Financial Statements and Exhibits.
(d)
Exhibits
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.
|
|
|
|
|
|
|
|
|
|
|
|
|
AKEBIA THERAPEUTICS, INC.
|
|
|
|
|
Date: May 9, 2019
|
|
|
|
By:
|
|
/s/ John P. Butler
|
|
|
|
|
|
|
Name: John P. Butler
Title: President and Chief Executive Officer
|
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From Apr 2024 to May 2024
Akebia Therapeutics (NASDAQ:AKBA)
Historical Stock Chart
From May 2023 to May 2024